CVRx (NASDAQ:CVRX) versus Inogen (NASDAQ:INGN) Head to Head Contrast

CVRx (NASDAQ:CVRX) and Inogen (NASDAQ:INGN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations and institutional ownership.

Analyst Recommendations

This is a summary of current recommendations and price targets for CVRx and Inogen, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CVRx	1	0	5	1	2.86
Inogen	0	1	1	0	2.50

CVRx currently has a consensus price target of $14.00, indicating a potential upside of 91.26%. Inogen has a consensus price target of $11.00, indicating a potential upside of 30.02%. Given CVRx’s stronger consensus rating and higher possible upside, research analysts plainly believe CVRx is more favorable than Inogen.

Insider & Institutional Ownership

75.3% of CVRx shares are held by institutional investors. Comparatively, 89.9% of Inogen shares are held by institutional investors. 13.9% of CVRx shares are held by company insiders. Comparatively, 1.5% of Inogen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Volatility & Risk

CVRx has a beta of 1.26, indicating that its stock price is 26% more volatile than the S&P 500. Comparatively, Inogen has a beta of 1.78, indicating that its stock price is 78% more volatile than the S&P 500.

Profitability

This table compares CVRx and Inogen’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CVRx	-95.61%	-79.31%	-40.96%
Inogen	-7.58%	-13.77%	-8.52%

Earnings & Valuation

This table compares CVRx and Inogen”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CVRx	$51.29 million	3.73	-$59.97 million	($2.10)	-3.49
Inogen	$335.70 million	0.68	-$35.89 million	($1.06)	-7.98

Inogen has higher revenue and earnings than CVRx. Inogen is trading at a lower price-to-earnings ratio than CVRx, indicating that it is currently the more affordable of the two stocks.

Summary

Inogen beats CVRx on 8 of the 15 factors compared between the two stocks.

About CVRx

CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

About Inogen

Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Simeox airway clearance; batteries; and related accessories. It also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.